Full history for every metric is available with a Kvantra account
Mind Medicine (MindMed) Inc. (MMED.NE)
Key financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | $m | -104 | -130 | |||||
| Net profit | $m | -18 | -34 | -93 | -57 | -96 | -109 | -115 |
| EPS reported | $ | -2.27 | -2.40 | |||||
| Operating cashflow per share | $ | -1.65 | -1.23 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -1.65 | -1.23 | |||||
| Free cash flow | $m | -79 | -102 | |||||
| Net debt | $m | -252 | -142 | |||||
| Book value equity | $m | 241 | 185 | |||||
| Book value per share | $ | 5.04 | 3.87 | |||||
| Number of shares | m | 47.86 | 47.86 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 2.05 | 3.98 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | -6.26 | -7.26 | |||||
| EV/EBITDA LTM | x | -2.35 | -5.44 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | -21.93% | -13.21% | |||||
| FCF Yield | % | -15.97% | -13.78% | |||||
| Quality | ||||||||
| ROE | % | -45.01% | -32.38% | |||||
| ROIC | % | -39.47% | -32.17% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -3.62 | -2.47 | |||||
| Net Debt/EBITDA | x | 2.42 | -0.12 | |||||
| EBIT/Net interest | x | 0.00 | -24.85 | |||||
| Net debt/market cap | % | -50.83% | -19.23% | |||||
| Net debt/Equity | x | -1.04 | -0.76 | |||||
| Gross debt/equity | x | 0.09 | 0.22 | |||||
Company overview
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company focused on creating innovative treatments for various brain health conditions, encompassing psychiatric, addiction, pain, and neurological disorders. Its product pipeline includes MM-120, currently in Phase 2 clinical trials for its potential to address generalized anxiety disorder, attention deficit hyperactivity disorder, and chronic pain. Additionally, the company is advancing MM-110, an a3ß4 nicotinic cholinergic receptor antagonist, which has completed Phase 1 development as a therapy for opioid withdrawal. MindMed is also developing MM-402, an R-enantiomer of 3,4-methylenedioxymethamphetamine, aimed at treating the primary symptoms of autism spectrum disorder. The company's operations are headquartered in New York, New York.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Mind Medicine (MindMed) Inc. (MMED.NE)
Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company focused on creating innovative treatments for various brain health conditions, encompassing psychiatric, addiction, pain, and neurological disorders. Its product pipeline includes MM-120, currently in Phase 2 clinical trials for its potential to address generalized anxiety disorder, attention deficit hyperactivity disorder, and chronic pain. Additionally, the company is advancing MM-110, an a3ß4 nicotinic cholinergic receptor antagonist, which has completed Phase 1 development as a therapy for opioid withdrawal. MindMed is also developing MM-402, an R-enantiomer of 3,4-methylenedioxymethamphetamine, aimed at treating the primary symptoms of autism spectrum disorder. The company's operations are headquartered in New York, New York.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free